Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Precision Molecular
Gaithersburg, Maryland, United Statesprecisionmol.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
PMI21 (astatine-211-labeled PSMA inhibitor) is in IND-enabling studies, expected to enter clinical trials for metastatic prostate cancer. PMI06 (radiolabeled PD-L1 peptide for PET imaging) is entering Phase 1 clinical trials for quantifying PD-L1 in solid tumors.
- Therapeutic areas
- Oncology
- Modalities
- RadiopharmaceuticalPeptides
- Industry
- Biotech
02
Partnerships
Johns Hopkins University (exclusive licensing)
Beyond the preview
Go deeper on Precision Molecular.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Precision Molecular.